Sravathi AI Technology Pvt Ltd. has disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
Researchers from University of Padova have presented data from a study that aimed to investigate the role of microRNAs (miRs) in the development and progression of inflammatory bowel disease (IBD)-related colorectal cancer (CRC).
Jacobio Pharmaceuticals Group Co. Ltd. has received FDA approval of its IND application for JAB-30300, allowing it begin a phase I/IIa trial in the U.S. in advanced solid tumors.
Neurenati Therapeutics has closed its seed funding round, securing CA$1.2 million (US$884,000) to advance development of therapies for various rare diseases, including pediatric conditions.
At this week’s EACR-AACR-ICAR meeting in Dublin, Suzhou Kintor Pharmaceuticals Inc. presented preclinical data for the novel MYC- and GSPT1-targeting molecular glue candidate, GT-19630, being developed for the treatment of breast cancer.
Tumors in the stomach and pancreas are known to express claudin 18.2 (CLDN18.2) and the absence of expression in normal tissues makes it an attractive therapeutic target.
Igc Pharma Inc. has reported results of preclinical studies investigating TGR-63 as a treatment for Alzheimer’s disease, showing enhanced memory function in an Alzheimer’s mouse model, including improved memory acquisition, consolidation and retrieval.
Psoriatic arthritis mutilans (PAM) is a rare variant and the most severe form of psoriatic arthritis where patients present erosions of the small joints and osteolysis leading to joint disruption and shortening of one or more digits. To date, no susceptibility genes have been determined.
Imunon Inc. has released promising results from a live virus challenge study conducted by the Wistar Institute with IMNN-101 against the SARS-CoV-2 variant XBB.1.5. This study was conducted using the clinical vector that Imunon intends to bring into its phase I study during the second quarter, and showed IMNN-101 immunogenicity and protective activity in a live viral mouse challenge.
RSS
